Subscribe to RSS
DOI: 10.1055/a-2491-2141
Onasemnogene Abeparvovec is Safe in Hemolytic Disease of the Newborn: A Case Report
Abstract
Spinal muscular atrophy (SMA) is a rare autosomal recessive genetic disease caused by Survival Motor Protein 1 (SMN1) gene mutations. Classically divided into three types, SMA is characterized by hypotonia, weakness, and tongue fasciculation in the first 6 months of life in type 1, inability to walk and limb weakness in type 2, and failure to run with proximal weakness in type 3 SMA. With the advent of newborn screening, treating presymptomatic patients with Onasemnogene abeparvovec (OA) is the treatment of choice in some centers worldwide. The incidence of jaundice is high in this age group, with no recommendation to guide the use of OA in newborns with jaundice. To our knowledge, treating an SMA patient with alloimmune hemolytic disease of the newborn (HDN), a relatively common disease in the newborn period, has never been reported in the past. We report our experience with dosing a presymptomatic child with SMA who had neonatal jaundice and hemolytic anemia due to hemolytic disease of the newborn who tolerated the treatment well. To our knowledge, this is the first case to report the safety of this novel treatment for an SMA patient with alloimmune HDN.
Keywords
onasemnogene abeparvovec - hemolytic disease of the newborn - neonatal jaundice - spinal muscular atrophyAuthors' Contributions
All the authors have read the paper and agreed on its content.
Publication History
Received: 30 August 2024
Accepted: 21 November 2024
Article published online:
17 December 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol 2011; 68 (08) 979-984
- 2 Angilletta I, Ferrante R, Giansante R. et al. Spinal muscular atrophy: an evolving scenario through new perspectives in diagnosis and advances in therapies. Int J Mol Sci 2023; 24 (19) 14873
- 3 Prior TW, Leach ME, Finanger E. Spinal muscular atrophy. In: Adam MP, Feldman J, Mirzaa GM. et al., eds. GeneReviews®. Seattle (WA): University of Washington; 1993. . Accessed July 25, 2024 at: http://www.ncbi.nlm.nih.gov/books/NBK1352/
- 4 Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 2015; 51 (02) 157-167
- 5 Mendell JR, Al-Zaidy S, Shell R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017; 377 (18) 1713-1722
- 6 Universal Newborn Screening for Spinal Muscular Atrophy | Neurology | JAMA Pediatrics | JAMA Network. Accessed July 25, 2024 at: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2817306
- 7 Nigro E, Grunebaum E, Kamath B. et al. Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment. Front Neurol 2023; 14: 1230889
- 8 Bhutani VK, Zipursky A, Blencowe H. et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res 2013; 74 (Suppl. 01) 86-100
- 9 Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology (Am Soc Hematol Educ Program) 2015; 2015 (01) 146-151
- 10 Chávez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA 1991; 265 (24) 3270-3274
- 11 Özcan M, Sevinç S, Erkan VB, Yurdugül Y, Sarıcı SÜ. Hyperbilirubinemia due to minor blood group (anti-E) incompatibility in a newborn: a case report. Turk Pediatri Ars 2017; 52 (03) 162-164
- 12 Agrawal A, Hussain KS, Kumar A. Minor blood group incompatibility due to blood groups other than Rh(D) leading to hemolytic disease of fetus and newborn: a need for routine antibody screening during pregnancy. Intractable Rare Dis Res 2020; 9 (01) 43-47
- 13 Dean L. The MNS blood group. In: Blood Groups and Red Cell Antigens. US: National Center for Biotechnology Information; 2005. . Accessed July 25, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK2274/
- 14 Novartis. Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset. Accessed March 25, 2024 at: https://www.novartis.com/news/media-releases/novartis-shares-zolgensma-long-term-data-demonstrating-sustained-durability-75-years-post-dosing-100-achievement-all-assessed-milestones-children-treated-prior-sma-symptom-onset
- 15 European Medicines Agency. Zolgensma. 2020 . Accessed October 2024 at: https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma
- 16 Novartis. Zolgensma Global Managed Access Program in 2023. 2023 . Accessed October 15, 2024 at: https://www.novartis.com/news/zolgensma-global-managed-access-program-2023
- 17 Chand D, Mohr F, McMillan H. et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol 2021; 74 (03) 560-566
- 18 Lindenburg ITM, van Kamp IL, Oepkes D. Intrauterine blood transfusion: current indications and associated risks. Fetal Diagn Ther 2014; 36 (04) 263-271
- 19 Day JW, Finkel RS, Mercuri E. et al. Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Mol Ther Methods Clin Dev 2021; 21: 76-82